Purpose: In developing countries, availability and quality of drugs are critical factors for effective management and control of epilepsy. This study investigated the availability and costs of antiepileptic drugs (AEDs), and the quality of phenobarbital in Vientiane Municipality, Lao PDR.
Methods: In March 2004, we enrolled all pharmacies (categories I and II) of four central districts of Vientiane eligible to sell AEDs. Two hundred and eight pharmacies of category III (75.1% of all registered pharmacies) were excluded as the sale of AEDs was not authorized. All pharmacists were interviewed with a standard questionnaire. Whenever phenobarbital was available, a sample was purchased and assayed by liquid chromatography. Phenobarbital was defined as being of correct quality if the active substance average content corresponded to +/-15% of the indicated amount.
Results: 66 pharmacies were enrolled (13 and 45 of categories I and II, respectively, and 8 hospital pharmacies). Six generics of AEDs were found (phenobarbital, phenytoin, valproic acid, clonazepam, carbamazepine, diazepam) and all pharmacies sold at least 1 AED. The 2 most widely available drugs were diazepam (5 mg) and phenobarbital (100 mg), present in 87.9 and 53.0% of the pharmacies, respectively. All 34 phenobarbital samples examined showed a correct concentration of the active compound. However, the concentration of phenobarbital 100 mg tablets produced in Lao PDR (mean concentration 94.7 mg) was significantly lower (p = 0.005) than the imported equivalent (mean concentration 99.7 mg). The direct drug costs of a yearly treatment with phenobarbital were estimated to be at least 25.2 USD.
Conclusions: A variety of AEDs are present. Their availability, particularly of phenobarbital, is restricted to higher-category pharmacies and within those it is rather limited. To meet the costs of AEDs in this setting is a major challenge for people with epilepsy. However, the quality of the available phenobarbital was rather satisfactory.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000103270 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Therapeutic Options for Crigler-Najjar Syndrome: A Scoping Review.
Int J Mol Sci
October 2024
Pediatric Clinic, Department of Medicine and Surgery, University Hospital of Parma, 43126 Parma, Italy.
Article Synopsis
- Crigler-Najjar Syndrome (CNS) is a rare genetic disorder that leads to severe jaundice due to impaired processing of bilirubin, with two forms: CNS type 1 (more severe) and CNS type 2 (milder).
- The management of CNS1 is aggressive, often requiring liver transplantation as the only definitive treatment, while CNS2 can be managed with medications like phenobarbital.
- New therapies, including gene therapy and autologous hepatocyte transplantation, are emerging as potential alternatives to surgery, aiming to enhance treatment effectiveness and improve life quality for CNS patients.
Advances in serum thyroid hormone levels and seizures.
Epilepsy Behav
November 2024
The Affiliated Lianyungang Hospital of Xuzhou Medical University, China. Electronic address:
Article Synopsis
- Epilepsy is a neurological disorder that affects quality of life and involves changes in brain activity, neurotransmitter imbalances, and GABA receptor dysfunction, with its causes still not fully understood.
- Thyroid hormones are important for brain function and can influence seizure activity by regulating oxidative stress and neurotransmitter levels, so defects in their signaling may lead to more frequent seizures and neurodevelopmental disorders.
- Traditional antiseizure medications may disrupt thyroid hormone levels, with some, like phenobarbital and carbamazepine, potentially causing hypothyroidism, while newer medications like levetiracetam don’t impact thyroid levels, highlighting the complex interplay between seizures and thyroid hormone dynamics.
Article Synopsis
- - Alcohol use disorder is prevalent in the U.S., and while benzodiazepines are typically recommended for alcohol withdrawal syndrome (AWS), there’s a growing trend to use phenobarbital, especially for patients at high risk of severe AWS.
- - A quality improvement study at a medical institution evaluated the effectiveness of a phenobarbital-based treatment protocol for AWS, measuring rates of protocol adherence and clinical outcomes before and after implementation.
- - Results showed a significant increase in the administration of phenobarbital, a decrease in the combined use of benzodiazepines, and a reduction in total benzodiazepine dosage, with improved safety outcomes such as fewer days in the ICU for those transferred.
The Impact of Sedative Choice in the Management of Aneurysmal Subarachnoid Hemorrhage: A Scoping Review.
Neurocrit Care
September 2024
Department of Intensive Care, The Alfred Hospital, Melbourne, VIC, Australia.
Aneurysmal subarachnoid hemorrhage (aSAH) is characterized by high mortality and morbidity. This scoping review assesses the current evidence regarding the use of sedatives and analgesics in the acute intensive care unit management of aSAH. We conducted a systematic search of Ovid MEDLINE, Ovid Embase, Ovid EmCare, APA PsycInfo, CINAHL, and the Cochrane Database of Systematic Reviews from inception to June 2023.
View Article and Find Full Text PDFBackground: Alcohol withdrawal syndrome (AWS) is highly prevalent in hospital inpatients. Recent evidence supports use of phenobarbital and gabapentin in certain patients, and screening tools for severe withdrawal risk can be used to guide care. Inpatients with AWS should also be considered for evidence-based treatment for alcohol use disorder (AUD).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!